Clinical trial · Observational
Optical Detection of Malignancy During Percutaneous Interventions
Discrimination of Benign and Malignant Human Tissue During Percutaneous Interventions Using Optical Spectroscopy Techniques
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigation of application possibilities of optical spectroscopy within the field of oncology. Optical spectroscopy enables the possibility to specifically differentiate between different (human) tissues. The hypothesis is that incorporation of this technique into existing medical devices (e.g. biopsy needle) would enlarge the accuracy and reliability of these devices. The purpose is to improve and speed up the diagnostics and therapy of the malignancies.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Colon Cancer Liver Metastasis | — | UNRESOLVED | — |
| Pulmonary Coin Lesion | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Core biopsy procedure | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Histological biopsy procedures
- description
- Patients with a suspicious lesion in lung or liver or breast who are planned for a standard core biopsy procedure. And patients planned for percutaneous RFA (Radiofrequency Ablation) of colorectal liver metastasis
- interventionNames
- Procedure: Core biopsy procedure
Primary outcomes (1)
- measure
- Differentiation between normal and malignant tissue
- timeFrame
- Day 0
- description
- Statistical analysis of the difference between diffuse reflectance spectra obtained at normal and malignant measurement locations
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a suspicious lesion in lung or liver who are scheduled for a standard core biopsy procedure * Patient planned for percutaneous RFA of colorectal liver metastasis * Written informed consent * Patients ≥ 18 years old * Breast patients with a BIRADS score 4 or 5 General Exclusion criteria: * Patients who have higher risk of bleeding * Patients with suspected sensitivity to light; e.g. patients who have had photodynamic therapy Breast Specific Exclusion criteria: * Patients who have a history of breast cancer and/or who have received prior chemotherapy, endocrine therapy, or radiation therapy * Patients who have breast implants * Patients needing a stereotactic breast biopsy (i.e. non palpable-, ultrasound opaque lesions)
References
Publications (1)
- DERIVEDde Boer LL, Bydlon TM, van Duijnhoven F, Vranken Peeters MTFD, Loo CE, Winter-Warnars GAO, Sanders J, Sterenborg HJCM, Hendriks BHW, Ruers TJM. Towards the use of diffuse reflectance spectroscopy for real-time in vivo detection of breast cancer during surgery. J Transl Med. 2018 Dec 19;16(1):367. doi: 10.1186/s12967-018-1747-5. PMID 30567584